作者
Mikiko Tokunaga, Kazuyoshi Saito, Daisuke Kawabata, Yoshitaka Imura, Takao Fujii, Shingo Nakayamada, Shizuyo Tsujimura, Masao Nawata, Shigeru Iwata, Taeko Azuma, Tsuneyo Mimori, Yoshiya Tanaka
发表日期
2007/4/1
期刊
Annals of the rheumatic diseases
卷号
66
期号
4
页码范围
470-475
出版商
BMJ Publishing Group Ltd
简介
Aim: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious treatment-resistant phenotype of systemic lupus erythematosus. A standard treatment for NPSLE is not available. This report describes the clinical and laboratory tests of 10 patients with NPSLE before and after rituximab treatment, including changes in lymphocyte phenotypes.
Methods: Rituximab was administered at different doses in 10 patients with refractory NPSLE, despite intensive treatment.
Results: Treatment with rituximab resulted in rapid improvement of central nervous system-related manifestations, particularly acute confusional state. Rituximab also improved cognitive dysfunction, psychosis and seizure, and reduced the SLE Disease Activity Index Score at day 28 in all 10 patients. These effects lasted for >1 year in five patients. Flow cytometric analysis showed that rituximab down regulated CD40 and CD80 on B cells …
引用总数
学术搜索中的文章
M Tokunaga, K Saito, D Kawabata, Y Imura, T Fujii… - Annals of the rheumatic diseases, 2007